September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The withdrawal rate of oral and topical corticosteroids in vernal keratoconjunctivitis
after topical immunosuppresants.
Author Affiliations & Notes
  • Mika Shinoda
    Fukuoka University, Fukuoka, Japan
  • YUSUKE SAEKI
    Fukuoka University, Fukuoka, Japan
  • Jane Huang
    Fukuoka University, Fukuoka, Japan
  • Tomoko Tsukahara
    Fukuoka University, Fukuoka, Japan
  • Eiichi Uchio
    Fukuoka University, Fukuoka, Japan
  • Footnotes
    Commercial Relationships   Mika Shinoda, None; YUSUKE SAEKI, None; Jane Huang, None; Tomoko Tsukahara, None; Eiichi Uchio, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3501. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mika Shinoda, YUSUKE SAEKI, Jane Huang, Tomoko Tsukahara, Eiichi Uchio; The withdrawal rate of oral and topical corticosteroids in vernal keratoconjunctivitis
      after topical immunosuppresants.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3501.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The treatment of vernal keratoconjunctivitis (VKC) has been shifted from the use of corticosteroids into cyclosporine and tacrolimus in recent years. Our purpose of this study is to report the withdrawal rate of topical and/or oral corticosteroids in VKC after topical treatment of immunosuppresants and subcutaneous triamcinolone acetonide eyelid (STAE) injection at Fukuoka University Hospital.

Methods : This study involved 50 eyes of 25 VKC patients (19 males and 6 females). Their age ranged from 4 to 26 years old (average 10.6 years old). The withdrawal rate of topical and/or oral corticosteroids and the clinical scores of keratoconjunctive were evaluated at their first visit, 1 month, 3 months, 6 months, and 12 months after the initiation of the use of topical immunosuppressants and STAE injection.

Results : The clinical scores of keratoconjunctive was 9.5±0.5 (average ± standard deviation) at their first visit, 5.4±0.4 at 1 month, 3.8±0.4 at 3 months, 3.3±0.8 at 6 months, and 3.3±0.8 at 12 months. The withdrawal rate of corticosteroid was 64.0% at 1 month, 70.0% at 3 months, 74.0% at 6 months, and 80.0% at 12 months after the initiation of the treatment, respectively. Fourty-five eyes was started using topical tacrolimus at first visit. After 12 months, the rate of use of tacrolimus was 85.4%.

Conclusions : The treatment of topical corticosteroids could be reduced or stopped the use of topical immunosuppressants in VKC and STAE injection for VKC had the additional effect. These local treatments seemed to be useful in symptomatic improvement and long-term clinical resolution.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×